Loading stock data…
Kymera Therapeutics, Inc. (KYMR)
$116.47-0.92 (-0.78%)
Market ClosedLast close Sep 8
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Kymera Therapeutics, Inc. in the Healthcare sector is trading at $116.47 with a market capitalization of $6.0B. Wall Street consensus targets $134.71 (21 analysts), implying a +15.7% move over the next 12 months. The stock is currently near its 52-week high of $130.05, remaining 30.4% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +15.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $65.00M↑ | $34.37M↑ | $2.87M↑ | $2.76M↓ | $11.48M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$75.61M↑ | -$84.15M↑ | -$97.90M↓ | -$88.67M↓ | -$84.56M |
| Net Income | -$61.21M↑ | -$69.23M↑ | -$86.98M↓ | -$82.17M↓ | -$76.61M |
Peer Comparison
JNJUNHPFE
Fundamentals
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.02B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.06
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-20.46%
Volume
Today's trading volume
631,280
Recent News
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027.
Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says
Kymera Therapeutics' (KYMR) KT-621 could validate its "oral Dupixent" potential, but with a roughly
Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript
Enrollment completed six months early; $1.5B cash runway into 2029.
Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says
Nurix Therapeutics' (NRIX) STAT6 degrader NX-3911 is likely to receive increased recognition after a